Medical Applications of Rifaximin

Date：2019-01-01

Rifaximin, a rifamycin derivative, is the first non-aminoglycoside intestinal antibiotic. It has a strong effect, a wide antibacterial spectrum, and is highly active against staphylococcus aureus, staphylococcus epidermidis, and streptococcus faecalis among gram-positive aerobic bacteria; salmonella spp., escherichia coli, helicobacter spp., yersinia enterocolitica, and cocci among gram-negative irregular aerobic bacteria; and bacteroides spp., among gram-negative anaerobic bacteria. rifoxifene can be used to treat diseases caused by aerobic and anaerobic bacteria, such as irritable bowel syndrome, hepatic encephalopathy, and traveler's diarrhea. rifoxifene has the advantage that it is not absorbed and is not present in other organs. Compared with other aminoglycoside antibiotics, it does not damage auditory function; it does not cause renal insufficiency; parasitic normal bacteria, especially intestinal non-pathogenic E. coli, are quickly rescheduled to the intestine to avoid superinfection; and intestinal mucosal inflammation tends to disappear.